| Size | Price | Stock |
|---|---|---|
| 1mg | $395 | In-stock |
| 5mg | $990 | In-stock |
| 10mg | $1585 | In-stock |
| 25mg | $2950 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-112811 |
| M.Wt: | 748.74 |
| Formula: | C39H36N6O10 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
PROTAC CDK9 degrader-2 is a PROTAC degrader targeting CDK9, with an IC50 of 523 nM. PROTAC CDK9 degrader-2 selectively degrades CDK9 via the cereblon-dependent ubiquitin-proteasome pathway and inhibits the proliferation of cancer cells overexpressing CDK9. PROTAC CDK9 degrader-2 can be used for cancer research[1].
IC50 & Target:IC50: 17 μM (CDK9, MCF-7 cells)[1]
In Vitro:PROTAC CDK9 degrader-2 (compound 11c, 1-30 μM, 24 h) selectively induces concentration-dependent, proteasome-dependent, and CRBN-dependent degradation of CDK9 and its downstream Mcl-1 protein in MCF-7 cells[1].
PROTAC CDK9 degrader-2 (72 h) selectively inhibits the proliferation of MCF-7 cells with overexpressed CDK9, with an IC50 of 17 μM, while its activity against L02 cells with low CDK9 expression is negligible[1].
PROTAC CDK9 degrader-2 (10-20 μM; 24 h) induces dose-dependent apoptosis in MCF-7 cells following incubation at concentrations of 10 μM and 20 μM for 24 h[1].
PROTAC CDK9 degrader-2 (1 μM; 1 h) potently inhibits the kinase activity of recombinant CDK9/CycT1, with an IC50 value of 523 nM[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.